688082:SSEACM Research (Shanghai), Inc. Class A Analysis
Data as of 2026-03-17 - not real-time
CN¥153.43
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
ACM Research (Shanghai) is trading at a price of roughly CNY 153, which sits just above the 200‑day SMA of 153.1 and well below the 20‑day SMA of 167.3, indicating a short‑term pull‑back within a longer‑term uptrend. The RSI of 34.7 suggests the stock is approaching oversold territory, while a bearish MACD histogram (-0.82) and a negative MACD signal line reinforce recent downside momentum. The current price is near the identified support level of 150.5 and still far from the resistance at 189, leaving limited upside in the near term. Fundamentally, the company carries a trailing P/E of ~50 versus an industry average of 34, and a DCF‑derived fair value of only CNY 16.5, signaling significant overvaluation. Nevertheless, the latest earnings release highlighted a 15% revenue growth in 2025, driven by strong cleaning and plating solutions, and the firm maintains a modest dividend yield of 0.42% with a low payout ratio of 21%.
The balance sheet shows ample cash (CNY 7.5 bn) against debt (CNY 1.9 bn), but free cash flow remains negative, raising concerns about dividend sustainability. High 30‑day volatility (≈46%) and a near‑zero beta (-0.09) point to a stock that is both volatile and largely uncorrelated with broader market moves. Combined with medium‑high sector and regulatory risks in China’s semiconductor equipment space, the outlook leans toward caution despite the recent earnings beat.
The balance sheet shows ample cash (CNY 7.5 bn) against debt (CNY 1.9 bn), but free cash flow remains negative, raising concerns about dividend sustainability. High 30‑day volatility (≈46%) and a near‑zero beta (-0.09) point to a stock that is both volatile and largely uncorrelated with broader market moves. Combined with medium‑high sector and regulatory risks in China’s semiconductor equipment space, the outlook leans toward caution despite the recent earnings beat.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above key support (150.5)
- Bearish MACD yet RSI near oversold levels
- Decreasing volume indicating limited buying pressure
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- 15% YoY revenue growth reported in Q4 2025
- Persistently high P/E relative to peers
- Negative free cash flow despite strong cash reserves
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- DCF fair value far below market price
- Overvaluation evident from P/E and price‑to‑book multiples
- High sector cyclicality and regulatory uncertainty in China
Key Metrics & Analysis
Financial Health
Revenue Growth-0.10%
Profit Margin20.57%
P/E Ratio50.0
ROE13.20%
ROA5.00%
Debt/Equity14.01
P/B Ratio5.5
Op. Cash FlowCN¥238.8M
Free Cash FlowCN¥-775225728
Industry P/E34.2
Technical Analysis
TrendNeutral
RSI34.7
SupportCN¥150.51
ResistanceCN¥188.98
MA 20CN¥167.30
MA 50CN¥181.68
MA 200CN¥153.12
MACDBearish
VolumeDecreasing
Fear & Greed Index79.98
Valuation
Fair ValueCN¥16.48
GradeOvervalued
TypeGrowth
Dividend Yield0.42%
Risk Assessment
Beta-0.09
Volatility46.69%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.